Cel-sci Corp (NYSEMKT:CVM)

CAPS Rating: 1 out of 5

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer.

CVM News and Commentary

Caps

How do you think CVM will perform against the market?

Add Stock to CAPS Watchlist

All Players

87 Outperform
25 Underperform
 

All-Star Players

8 Outperform
10 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top CVM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ejad1 (< 20)
Submitted January 16, 2014

CVM is expecting to conclude its phase III of Multikrine end 2014 or early 2015

DigitalDisco (89.71)
Submitted June 15, 2017

reverse split

CVM VS S&P 500 (SPY)

Fools bullish on CVM are also bullish on:

Fools bearish on CVM are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CVM.

Recs

1
Member Avatar DigitalDisco (89.71) Submitted: 6/15/2017 12:49:23 PM : Underperform Start Price: $1.78 CVM Score: +8.81

reverse split

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 6/5/2016 8:17:00 AM : Underperform Start Price: $13.12 CVM Score: +113.21

Has it really been over a year since I looked at Cel-Sci? I knew my life was missing something. Catching up was very entertaining. Things are as scuzzy and futile as ever over at Cel-Sci.

Last February I pointed out that the company's claim of being on track to complete enrollment of the phase III trial in 2015 was obviously nonsensical, and of course as of now the trial is still enrolling. I expect enrollment will get completed this year, though. Of course, the year topline data will appear is still anyone's guess. Similarly, the phase I trial of MuliKine for anal warts which was supposed to complete enrollment in 2015 is still enrolling.

Again, as I pointed out last year, Cel-Sci has no money and funds their operations (and executive salaries) through a never-ending series of below-market dilutive financings juiced with low-strike warrants. I thought about reading the 10Q to see how many series of warrants are currently outstanding and decided not to bother. Suffice it to say that virtually nothing will be able to give this stock momentum with all the warrant exercising that will take place on any upward movement. In May, Cel-Sci raised 5M through yet another RDO with warrants, which will keep them solvent for this quarter. Not paying their bills also helps - check their mounting accounts payable line item on their quarterly balance sheets.

Desperate Cel-Sci bagholders also dream of a multimillion dollar windfall from a lawsuit against their former CRO. Don't bet on it. The trial was originally set for May 2015 but keeps getting mysteriously postponed. Management has lately been very vague about any timeline for resolution. They did use the services of vulture legal financier Lake Whillans to fund their lawsuit. Lake Whillans is named after a subglacial lake in Antarctica. I'll leave the construction of the metaphor to the reader. There's also a countersuit against Cel-Sci by the CRO, which I haven't seen the company mention in any of their PR.

The other ongoing thread through this swamp of burning cash is promotion. Cel-Sci has hired notorious boiler room Redchip to spread the good word via all forms of electronic communication. On Seeking Alpha we can find Sharon DiStefano and "Just One Lab Nerd" incessantly waxing lyrical about the commercial prospects of MultiKine and lionizing management for their flawless execution of their business plan, meanwhile ignoring the utter destruction of the company's capital structure and share price. Of course, Seeking Alpha writers are never compensated by the companies they write about. It's right there in the disclosure. But Sharon DiStefano is very cozy with management. They give her personalized guided tours of their facilities. I'm sure if I gave them a call, I'd get the same treatment (not that I want to waste a day at Cel-Sci).

50 cents may seem like a cheap price to buy a stock, but thanks to the 140M share count Cel-Sci has a 72M market cap. Compare that to the 30M shares of common stock they had after the reverse split in late 2013. That's almost 400% dilution in less than three years, not even counting the zillions of outstanding warrants. I think the next step for Cel-Sci will be another reverse split, followed by some lying, then dilution, promotion, dilution, then more lying. I'll be back next year to see how my predictions fared this time around.

Recs

3
Member Avatar asilverp (73.60) Submitted: 8/28/2014 12:28:41 PM : Underperform Start Price: $26.50 CVM Score: +126.81

Stats are terrible. At least 50% downside imho.

Leaderboard

Find the members with the highest scoring picks in CVM.

Score Leader

dexxyru

dexxyru (< 20) Score: +254.02

The Score Leader is the player with the highest score across all their picks in CVM.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
dexxyru < 20 9/24/2009 Underperform 5Y $397.50 -99.55% +154.49% +254.04 0 Comment
bermuda999 < 20 8/16/2010 Underperform 1Y $125.25 -98.56% +148.62% +247.18 0 Comment
DarthMaul09 29.05 10/16/2009 Underperform 5Y $387.50 -99.54% +145.81% +245.34 4 Comments
pennycruncher < 20 10/19/2009 Underperform 5Y $380.00 -99.53% +145.20% +244.73 0 Comment
arboretum 27.78 6/14/2010 Underperform 5Y $125.00 -98.56% +141.98% +240.54 0 Comment
qasamm 24.10 1/3/2011 Underperform 3M $209.88 -99.14% +111.06% +210.21 0 Comment
Rollme < 20 10/8/2013 Underperform 5Y $21.48 -91.62% +60.90% +152.52 0 Comment
remrem44 < 20 3/14/2014 Underperform 3Y $34.17 -94.73% +44.35% +139.08 0 Comment
MMCapitalMgmt 99.91 1/21/2014 Underperform 5Y $22.88 -92.13% +45.27% +137.40 0 Comment
kinosternon 99.49 2/28/2014 8/14/2017 Underperform 1Y $28.18 -93.61% +42.99% +136.61 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CVM.

Featured Broker Partners